---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-030851"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:35:21.914846+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Relmada Therapeutics updates corporate presentation, no financial data disclosed

## Summary
- Filed 8-K on April 19, 2023, to announce an updated corporate presentation.
- Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders' filed as Exhibit 99.1.
- No specific financial or operational milestones provided in the filing or exhibit text.
- CEO Sergio Traversa signed the filing; presentation may contain pipeline or strategy updates.

## SEC filing metadata
- accession: 0001213900-23-030851
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/0001213900-23-030851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/ea177149-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-030851
- JSON: https://secwatch.observer/filing/0001213900-23-030851.json
- Plain text: https://secwatch.observer/filing/0001213900-23-030851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.